2 mL Exacta-Med Oral Dispenser
Baxa Corp (Englewood, Colo) recently introduced the 2 mL Exacta-Med Oral Dispenser. The company's line of oral liquid medication dispensers is available in sizes from 0.5 mL to 60 mL. The addition of the 2-mL dispenser provides health professionals with the flexibility and convenience to meet the full range of their oral dosing needs. Exacta-Med Oral Dispensers play a vital role in preventing wrong-route administration of nonintravenous (IV) fluid drugs. The unique dispenser tip cannot connect to a Luer needle hub, needleless connector, or patient IV access device. Designed to ensure dose accuracy while preventing medication errors and wrong-route administration of IV drugs, oral dispensers and accessories are recommended by the Institute for Safe Medication Practices for use in oral and enteral fluid drug delivery. For more information call 800-567-BAXA (800-567-2292), or visit www.baxa.com.
Ampicillin and Sulbactam for Injection
Abraxis Pharmaceutical Products (Schaumburg, Ill) recently received FDA approval for its abbreviated new drug application for the combination drug ampicillin and sulbactam for injection 15 g pharmacy bulk pack. The product is AP-rated, latex-free, and the generic equivalent of Pfizer Inc's Unasyn. Ampicillin and sulbactam is an injectable antibacterial combination consisting of the semisynthetic antibiotic ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium. Administered intravenously or intramuscularly, the product is indicated for the treatment of several skin and skin structure, intra-abdominal, and gynecological infections due to susceptible strains of microorganisms. The product is also available in 1.5-g and 3-g single-dose vials. For more information call 800-551-7176, or visit www.appdrugs.com.
Bedford Laboratories (Bedford, Ohio), a division of Ben Venue Laboratories Inc, has begun shipping lorazepam injection. The product is AP-rated to Baxter Healthcare Corp's Ativan Injection. Lorazepam injection is indicated for the treatment of status epilepticus. The product is also indicated in adult patients for preanesthetic medication, producing sedation (sleepiness or drowsiness), relief of anxiety, and a decreased ability to recall events related to the day of surgery. Lorazepam injection is most useful in those patients who are anxious about their surgical procedure and who would prefer to have diminished recall of the events of the day of surgery. The product is available in a 2-mg/mL, 1-mL single-dose vial and a 10-mL multiple-dose vial, as well as a 4-mg/mL, 1-mL single-dose vial and a 10-mL multiple-dose vial. For more information, visit www.bedfordlabs.com, or call 800-521-5169.
Hospira Inc (Lake Forest, Ill) recently introduced the Symbiq infusion system, a medically and technologically advanced medication management system that combines ease of use, reliability, and next-generation technology. Infusion systems like Symbiq administer intravenous (IV) medications, fluids, and solutions to patients. It is critical for these devices to have safeguards, such as safety software and instinctive programming options, to help clinicians prevent medication errors. Symbiq is an "intelligent" pump that incorporates differentiated, clinician-friendly features to decrease errors and improve workflow. Symbiq's features include advanced infusion system with patient-safety software already integrated into the device to assure compliance; sophisticated reporting capabilities and support of hospital standardization; intuitive LCD display?similar to an automated teller machine screen?that features simple layouts and touch-activated buttons to help minimize errors; an easy-to-read display with large font and color prompts; quick-release pole clamp that enables clinicians to rapidly move or attach the system to an IV pole or bed rail; and an automatic medication-loading slot that allows easy and timesaving insertion of the medication administration set. For more information, visit www.hospira.com, or call 877-9HOSPIRA (877-946-7747).
Although the annual HIV diagnosis rate between 2010 and 2014 decreased for black individuals by 16.2%, blacks remain disproportionately affected by HIV/AIDS.
Clinical features with downloadable PDFs